US commerce secretary Howard Lutnick said trade talks with China were going well as the two sides met for a second day in London.
Investors are hoping for an improvement in ties after the relief around a preliminary deal struck last month gave way to fresh doubts when Washington accused Beijing of blocking exports critical to sectors such as aerospace, semiconductors and defence.
White House economic adviser Kevin Hassett said yesterday the US was likely to agree to lift export controls on some semiconductors in return for China speeding up the delivery of rare earths.
“The pause in tariff hostilities is a positive starting point as the US seeks the restoration of rare earth mineral exports from China which would inevitably result in a mutual relaxation,” Richard Hunter, head of markets at interactive investor, said in a morning note.
At 6.42am Dow E-minis were down 21 points, or 0.05%, S&P 500 E-minis were up 3.75 points, or 0.06%, and Nasdaq 100 E-minis were up 16 points, or 0.07%.
US equities rallied sharply in May, with the S&P 500 index and the tech-heavy Nasdaq marking their best monthly gains since November 2023, helped by upbeat earnings reports and a softening of President Donald Trump’s harsh trade stance.
The S&P 500 remains a little over 2% below all-time highs touched in February, while the Nasdaq is about 3% below its record peaks reached in December.
Investors are awaiting US consumer prices data tomorrow for clues on the Federal Reserve’s (Fed) rate trajectory.
While traders largely expect the Fed to keep interest rates unchanged next week, focus will be on any signs of pick-up in inflation as Trump’s tariffs risk raising price pressures.
Traders see at least two 25-basis point cuts by year-end, with a 63% chance of the first cut in September, according to the CME FedWatch tool.
Most megacap and growth stocks were mixed in premarket trading. Tesla shares advanced 2.2%.
Shares of vaccine makers dipped in premarket trading. Health secretary Robert F Kennedy Jr ousted all 17 members of a US Centers for Disease Control and Prevention panel of vaccine experts and is in the process of replacing them, his department announced yesterday.
Shares of vaccine maker Moderna were down 0.4% while Pfizer inched down 0.1%.
Recursion Pharmaceuticals advanced 2.5% after the biotech said it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged industry downturn.